<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MicroRNAs (miRNAs) are involved in sequence-specific cleavage, translational repression or deadenylation of specific target <z:chebi fb="2" ids="33699">mRNAs</z:chebi> resulting in post-transcriptional gene silencing </plain></SENT>
<SENT sid="1" pm="."><plain>Epstein-Barr Virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> induces cellular non-coding (nc)<z:chebi fb="40" ids="33697">RNAs</z:chebi> e.g., the "vault" <z:chebi fb="40" ids="33697">RNAs</z:chebi> or miRNAs such as miR-21, miR-155 or miR-146a </plain></SENT>
<SENT sid="2" pm="."><plain>MiR-146a is upregulated in various <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and plays a role in innate immunity </plain></SENT>
<SENT sid="3" pm="."><plain>We show that the EBV-encoded latent membrane protein 1 (LMP1) induces the expression of miR-146a via NFkappaB </plain></SENT>
<SENT sid="4" pm="."><plain>LMP1 activates the miR-146a promoter but not a promoter with a mutation of the NFkappaB-response elements </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely, a LMP1-mutant deficient in NFkappaB-activation failed to activate the promoter </plain></SENT>
<SENT sid="6" pm="."><plain>The "CAO"-LMP1 variant which has an increased potential to induce NFkappaB also showed a higher ability to activate the miR-146a promoter as compared to standard B95.8-LMP1 </plain></SENT>
<SENT sid="7" pm="."><plain>Northern blotting revealed high levels of miR-146a and miR-155 in the Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line Jijoye which expresses LMP1 while the LMP1-deficient P3HR1 mutant derived from Jijoye expresses less miR-146a or miR-155 </plain></SENT>
<SENT sid="8" pm="."><plain>Likewise, EBV-latency type I Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells with low LMP1 levels also contain low levels of either miR-146a or miR-155 while their levels are increased in LMP1-expressing EBV-latency type III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="9" pm="."><plain>Expression of LMP1 in P3HR1 cells upregulates miR-146a levels </plain></SENT>
<SENT sid="10" pm="."><plain>Neither miR-146a nor miR-155 are detectable in BCBL-1 cells transformed by the Kaposi-<z:hpo ids='HP_0100242'>Sarcoma</z:hpo> <z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">Herpes</z:e> virus (KSHV/HHV8) </plain></SENT>
<SENT sid="11" pm="."><plain>It is possible that the induction of miR-146a plays a role in the induction or maintenance of EBV latency by modulating innate immune responses to the virus infected host cell </plain></SENT>
</text></document>